US 12128048
Combination therapies using PRMT5 inhibitors for the treatment of cancer
granted A61KA61K31/416A61K31/502
Quick answer
US patent 12128048 (Combination therapies using PRMT5 inhibitors for the treatment of cancer) held by Mirati Therapeutics, Inc. expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Mirati Therapeutics, Inc.
- Grant date
- Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K31/416, A61K31/502, A61K31/517, A61K31/519